Alpha Lipoic Acid Supplements Manufacturer | OEM & Private Label ALA Solutions

ALA projects often fail in scale-up when treated like a simple commodity vitamin fill. Below is how we usually lock decisions before artwork and mass production.

Stability Management

What goes wrong: Assay drift, caking, or shelf-life shortfalls when humidity and grade are not locked early — especially with R-ALA vs racemic ALA.

What we typically do:

• Weighing/blending under controlled humidity (project target often RH ≤ 40–45%)
• Lock grade on BOM: DL-ALA · R-ALA · Stabilized R-ALA · Sodium R-Lipoate
• Default pack path for sensitive lots: HDPE bottle + desiccant; foil pouch when needed
• Project-scoped stability checks (assay / appearance / odor) before commercial release

Confirm with us: target shelf life, destination climate, and exact grade name on COA — not “ALA 600 mg” alone.

→ Moisture Control & Stability Engineering

Odor Management

What goes wrong: Sulfur-like odor triggers consumer complaints in powders, stick packs, and weakly protected solid doses; different lots of the “same” grade can smell different.

What we typically do:

• Incoming sensory screening before pilot
• Prefer hard capsules or film-coated tablets for first launches
• Use delayed-release shells or film coating when odor risk is high
• Require customer approval samples for smell before scale-up — not after labels are printed

Confirm with us: format priority (capsule / tablet / powder / stick) and whether a flavored system is in scope.

High-Dose Formulation

What goes wrong: Forcing “one capsule = 600 mg” creates fill-weight variation, oversize shells, or compression failures — then costly reformulation.

Default manufacturable paths:

Confirm with us: one-unit vs split-serving preference before capsule size is locked.

Grade Lock (Do Not Skip)

RFQ must state DL-ALA / R-ALA / Stabilized R-ALA / Sodium R-Lipoate, dose per serving, dosage form, and one- vs two-unit preference. Source or grade changes require re-qualification — silent “same-name ALA” swaps are not used to keep supply moving.

Send Inquiry Now

Will each batch meet the agreed ALA specification? and Will the next order stay the same as the approved first order?

1. ALA Raw Material Release (What We Check Before Production)

We do not treat “ALA” as one interchangeable item. Before weighing starts, the lot must match the locked grade on your project file.

If the COA grade does not match the BOM grade, the material is not released for production.

2. In-Process & Finished Product Release

During and after manufacturing, we focus on the points that commonly cause ALA order problems:

• Fill / tablet weight control for high-dose programs
• Assay confirmation on the finished lot
• Content uniformity where applicable
• Dissolution where the dosage form requires it
• Odor / appearance check before shipment release when the format is sensitive (especially powders and lightly protected packs)

Retain samples are kept by lot so that if a buyer reports smell or potency issues later, we can compare against the shipped batch.

3. Reorder Continuity (How We Keep Batch 2 = Batch 1)

After the first commercial batch is approved:

• The BOM is frozen (ALA grade + supplier pathway + capsule/tablet/softgel system + desiccant / pack format)
• Reorder POs should reference the previous commercial lot / BOM version
• A supplier or grade change needs re-check (assay + odor + small pilot when needed) and written customer approval before full production
• Backup sources, if used, must be the same locked grade and pre-qualified — not a cheaper “also called ALA” substitute

4. What We Will Not Do to “Keep Supply Moving”

• Switch racemic ALA ↔ R-ALA / stabilized grades without written approval
• Ship while the COA pack is still incomplete
• Change critical process or packaging parameters after commercial lock without customer confirmation

Request COA Example Pack · Request Supply & Traceability Brief

Commercial shipments can be supplied with the documentation packs commonly required for quality release, import clearance, retailer onboarding, and customer audits. After launch, we support reorder continuity and structured quality-issue handling.

Documentation Commonly Provided

Product & batch documents

• Certificate of Analysis (COA)
• Product Specifications / TDS
• Stability documentation (where applicable)
• Allergen statements
• Non-GMO documentation (where applicable)
• Heavy metal and microbiological test reports
• Manufacturing / batch documentation
• Export documentation support

Third-party testing (project-scoped)

• Independent laboratory testing can be arranged when buyers, retailers, or destination markets require third-party verification
• Typical scopes: assay / identity confirmation, heavy metals, microbiology, and other agreed raw-material or finished-product items
• Reports are issued against the locked specification and lot number for audit use

Packaging material documents (when required)

• Food-contact / packaging compliance statements for bottles, liners, pouches, and film systems used on the project
• Plasticizer / migration-related test reports for plastic bags, films, or soft packaging when the destination market or customer brief requires them
• Other pack-material reports (e.g., heavy metals in packaging contact materials) can be added by project scope

Tell us the destination market and retailer checklist early — document packages differ by country and channel.

→ Regulatory Compliance Guide · Global Presences

Compliance Pathways

Manufacturing systems operate under internationally recognized standards, including:

• cGMP
• HACCP
• ISO Quality Management Systems
• FSSC 22000
• Halal
• Kosher

After-Sales & Brand Protection Process

If a quality concern appears after shipment, buyers usually need a fast, clear answer — not a long internal CAPA lecture. For ALA programs, we handle cases around the issues that most often affect brand reputation.

ALA cases we see most often

How a case is handled

1. Freeze first — identify affected lot(s), review what is still in warehouse / in transit, and stop further shipment of the suspect lot when needed
2. Compare evidence — open retain samples vs customer sample; check COA grade lock (DL-ALA / R-ALA / stabilized), desiccant & pack format vs frozen BOM, and fill/compression records for high-dose runs
3. Retest when needed — repeat assay / key tests in-house; arrange third-party retest if the buyer or market requires it
4. Decide & prevent — agree disposition (replace / resupply / conditional acceptance per contract), then lock any BOM, packaging, or process fix into the next reorder file

What you receive

• A short lot investigation summary (what was checked and the conclusion)
• A clear handling proposal for the affected goods
• Updated reorder controls so the approved fix stays locked for future POs

Request Document Pack Checklist · Request Quality Issue Handling Brief

Step 1 — Formula Discussion
Align category positioning, ALA vs R-ALA strategy, dosage form, claim constraints, and target markets.

Step 2 — Ingredient Selection & Prototype
Lock specifications, develop prototypes, and evaluate manufacturability (stability, odor, fill, packaging fit).

Step 3 — Testing & Approval
Confirm assay/quality checks and customer approval samples before artwork finalization where applicable.

Step 4 — Mass Production
Scale approved formulas under controlled manufacturing systems with batch traceability.

Step 5 — Packaging & Delivery
Complete packaging, documentation package, and shipment coordination for destination markets.

→ Supplement Development Guide · Processing Technologies · Confidentiality & IP Protection

Send Inquiry Now

MOQ varies by formula complexity, dosage form, packaging, and ingredient grade.

• Capsules: often from about 3,000–5,000 bottles (pilot options confirmed with quote)
• Tablets: often from about 5,000–10,000 bottles
• Softgels: project-based by fill and packaging
• Gummies: often from about 5,000–10,000 bottles
• Powder / premix: project-based (commonly from hundreds of kg)

Premium R-ALA or complex multi-actives may require higher practical MOQs than standard racemic ALA capsule programs because of raw material packing sizes and process setup.

Get MOQ Guidance

• Sample/prototype: approximately 7–15 days after formula confirmation
• Existing / private label formulas: approximately 4–8 weeks
• Customized formulations: approximately 6–10 weeks (often within a 30-60 day commercial production window after approvals)
• New development projects: subject to validation and approval timelines

Final lead times are confirmed after formula review, packaging selection, and order confirmation. Custom-printed packaging artwork approval should be included in the overall schedule.

Confirm Lead Time